Archive · 2 Jun 2025
CAR T-cell Therapy Shows Promise in Cancer Treatment
Scientists are testing a new treatment called CAR T-cell therapy to fight cancer.
They take immune cells, which are like tiny soldiers, and change them to better attack cancer cells.
Studies presented at a conference showed promising results, including improved survival rates in some patients with advanced gastric cancer, and tumor shrinkage in patients with aggressive brain cancer.
The therapy has also shown promising results for leukemia and lymphoma patients.
This therapy is being researched at multiple institutions.
Studies presented at ASCO 2025 show effectiveness of CAR T-cell therapy for certain cancers.
Satri-cel CAR T-cell therapy showed increased progression-free and overall survival in phase 2 trials for advanced gastric cancer.
Researchers from University of Pennsylvania saw tumor regression in 62% of glioblastoma patients.
CAR T-cell therapy slowed tumor growth in aggressive brain cancer.
Results of studies were published in journals like The Lancet and Nature Medicine.
- Who
- Researchers from various institutions, including Peking University Cancer Hospital and Institute, University of Pennsylvania, and Indian Institute of Technology-Bombay.
- What
- Studies presented at ASCO 2025 show effectiveness of CAR T-cell therapy.
- When
- May 30 to June 3, 2025 (ASCO Meeting).
- Where
- Chicago, US
- Why
- To evaluate the effectiveness of CAR T-cell therapy against various cancers.
- Conference
- American Society of Clinical Oncology (ASCO) 2025
- Conference Dates and Location
- May 30 to June 3, Chicago, US
- Therapies Studied
- CAR T-cell therapy, Satri-cel
- Cancer Types Studied
- Advanced gastric/gastro-oesophageal junction cancer
- Trial Participants
- Phase 2 trial: 156 patients; Phase 1 trial: 18 patients
- Key Institutions
- University of Pennsylvania, Indian Institute of Technology-Bombay